Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells

Cancer Letters

Volumn 300, Issue 2, 2011, Pages 197-204

  Akao, Yukihiro ^a   Noguchi, Shunsuke ^a   Iio, Akio ^b   Kojima, Keitaro ^b   Takagi, Takeshi ^b   Naoe, Tomoki ^c  

^a GIFU UNIVERSITY   (Japan)

^b GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU; Colon cancer; Drug resistance; MiR 34a; Sirt1

Indexed keywords

BETA ACTIN; FLUOROURACIL; MICRORNA; MICRORNA 34A; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; SIRTUIN 1; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; E2F3 TRANSCRIPTION FACTOR; FLUOROURACIL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIRTUIN 1; TRANSFECTION;

EID: 78649633708     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.006     Document Type: Article

References (25)

1. Neuman H.B., Park J., Weiser M.R. Randomized clinical trials in colon cancer. Surg. Oncol. Clin. N. Am. 2010, 19:183-204.
2. Grávalos C., García-Escobar I., García-Alfonso P., Cassinello J., Malón D., Carrato A. Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin. Transl. Oncol. 2009, 11:526-533.
3. Lombardi L., Gebbia V., Silvestris N., Testa A., Colucci G., Maiello E. Adjuvant therapy in colon cancer. Oncology 2009, 77:50-56.
4. Caldas C., Brenton J.D. Sizing up miRNAs as cancer genes. Nat. Med. 2005, 11:712-714.
5. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
6. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
7. Cho W.C. MicroRNAs: potential biomarkers for cancer diagnosis prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 2010, 42:1273-1281.
8. Cho William C.S. Micrornas in cancer - from research to therapy. Biochem. Biophys. Acta - Rev. Cancer 2010, 1805:209-217.
9. Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 2008, 105:13421-13426.
10. Michan S., Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404:1-13.
11. Chu F., Chou P.M., Zheng X., Mirkin B.L., Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 2005, 65:10183-10187.
12. Jung-Hynes B., Nihal M., Zhong W., Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition. J. Biol. Chem. 2009, 284:3823-3832.
13. Kwon H.S., Ott M. The ups and downs of SIRT1. Trends Biochem. Sci. 2008, 33:517-525.
14. Kojima K., Ohhashi R., Fujita Y., Hamada N., Akao Y., Nozawa Y., Deguchi T., Ito M. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 2008, 373:423-428.
15. Fujita Y., Kojima K., Hamada N., Ohhashi R., Akao Y., Nozawa Y., Deguchi T., Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 2008, 377:114-119.
16. Akao Y., Nakagawa Y., Hirata I., Iio A., Ito T., Kojima K., Nakashima R., Kitade Y., Naoe T. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010, 17:398-408.
17. Welch C., Chen Y., Stallings R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26:5017-5022.
18. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. USA 2007, 104:15472-15477.
19. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., Arking D.E., Beer M.A., Maitra A., Mendell J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26:745-752.
20. Rokhlin O.W., Scheinker V.S., Taghiyev A.F., Bumcrot D., Glover R.A., Cohen M.B. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol. Ther. 2008, 7:1288-1296.
21. Hermeking H. P53 enters the microRNA world. Cancer Cell 2007, 12:414-418.
22. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 2007, 26:731-743.
23. Meijerman I., Beijnen J.H., Schellens J.H. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat. Rev. 2008, 34:505-520.
24. Yuan H., Li X., Wu J., Li J., Qu X., Xu W., Tang W. Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr. Med. Chem. 2008, 15:470-476. (Review).
25. Lee K.H., Chen Y.L., Yeh S.D., Hsiao M., Lin J.T., Goan Y.G., Lu P.J. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 2009, 28:3360-3370.